Vanda Pharmaceuticals Culture Company

Mr. Richard L. Gulino, also known as Rick, has been a Senior Vice President, Secretary and General Counsel of Vanda Pharmaceuticals Inc. since September 14, 2015. Mr. Gulino has more than 20 years of strategic and legal experience representing life sciences and healthcare companies. He served as Vice President and General Counsel at Ameritox, Ltd. He was responsible for all legal affairs of Ameritox including its corporate legal strategy, litigation, intellectual property and the management and coordination of outside counsel. He served as Vice President and Deputy General Counsel at Cephalon, Inc. where, he led the corporate & commercial legal function. He was employed at Cephalon,Inc. for more than 12 years in various roles. He finalized more than 20 major pharmaceutical product/technology licensing and strategic partnering agreements. He managed the corporate/commercial legal functions within the legal department and developed strategies for effectively handling intellectual property disputes and litigation. Before joining Cephalon, he served as a Senior Commercial Attorney at Zeneca, Inc. He was employed at AstraZeneca for seven years and worked in areas of acquisitions, divestitures, antitrust and compliance. Mr. Gulino began his legal career in private practice with Dow, Lohnes & Albertson in Washington, DC. He was a Founding Board Member and Secretary of the Cephalon Cares Foundation. He received his Bachelor of Arts in History from Colgate University and his Juris Doctor with high honors from Duke University School of Law.

Mr. Gunther Birznieks has been Senior Vice President of Business Development at Vanda Pharmaceuticals Inc. since March 2017 and served as its Vice President of Business Development until April 5, 2017. Mr. Birznieks held a number of positions at Vanda Pharmaceuticals including as Clinical Program Head of the tasimelteon and VSF-173 programs, Head of Informatics and in Singapore as Head of Operations. Mr. Birznieks previously spent the majority of his career in the areas of healthcare and biomedical informatics including bioinformatics support for microarray and genotyping projects with the Human Genome Project at NHGRI. Prior to joining to Vanda, Mr. Birznieks founded Extropia Pte Ltd., a Singaporean company which specialized in business and investment banking applications. Mr. Birznieks has published four books on computer technologies as well as numerous articles and talks on information security, programming and software development life cycle. He holds a B. A. in Psychology and M. S. in Computer Science from Johns Hopkins University.

Mr. Gian Piero Reverberi has been Senior Vice President of Vanda Pharmaceuticals, Inc. since September 8, 2015. Mr. Reverberi has been an Chief Commercial Officer of Vanda Pharmaceuticals, Inc. since April 2016. Mr. Reverberi served as European General Manager of Vanda Pharmaceuticals, Inc. since September 8, 2015 until June 8, 2016 and served as its Acting Chief Commercial Officer since December 2015. He acted as a corporate advisor supporting several companies in the development of their commercial and geographical expansion strategies. He served as Senior Vice President of International Specialty Pharma at Shire Pharmaceuticals, with responsibility for Shire's specialty pharma business in EMEA, Canada, Australia, Japan, Asia Pacific and Latin America. Prior to, he served as General Manager of Italy at Shire. Before joining Shire, he spent 10 years with Eli Lilly in Italy and the U.S. where he held several commercial positions including Business Unit Director (Diabetes Care) in Italy, District Manager and Business Development Leader in the U.S. Earlier in his career, he held finance positions in the U.S. and Italy with both Eli Lilly and IBM. He has more than 20 years of experience in the pharmaceutical industry, holding senior management and regional leadership positions over the last 10 years. Mr. Reverberi received his degree in Economics and Business Administration from Sapienza University of Rome and a Master in Business Administration from SDA Bocconi in Milan.

Mr. James Patrick Kelly, C.F.A., also known as Jim, has been the Chief Financial Officer and Treasurer at Vanda Pharmaceuticals Inc. since December 13, 2010 and its Executive Vice President since April 5, 2017. Mr. Kelly served as Secretary of Vanda Pharmaceuticals, Inc. from December 13, 2010 to September 14, 2015 and also served its Senior Vice President since December 13, 2010 until April 5, 2017. He has more than 18 years of experience in financial and operating roles within the healthcare and pharmaceutical industry. He has been a key member of MedImmune's financial leadership team since 2006. He joined MedImmune LLC., as Director of Sales and Marketing Finance and progressed to the role of Vice President, Controller. Prior to MedImmune and beginning in 2000, he was at Biogen Idec serving in research and development finance roles of increasing responsibility, as the Director of Planning and Operations. In that role, he was the Finance Leader for the global Development Organization and head of business operations for clinical functions. While at Biogen Idec, Mr. Kelly led the financial management of development and commercial collaborations which included 5 partners, 8 programs, 14 indications and over $1.7 billion in revenue. From 1997 to 2000, he was a member of the corporate finance team at Aetna Inc. which held a critical role in mergers and acquisitions and treasury management. During that period he participated in 11 transactions with a combined value of $20 billion. He began his life sciences career in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson. Mr. Kelly is a Chartered Financial Analyst and a Member of the Association of Bioscience Financial Officers. He holds his Master of Business Administration degree from Cornell University and his Bachelor of Sciences degree in Business Administration from the University of Vermont.

Mr. Vincent J. Milano, also known as Vinnie and Vin, has been the Chief Executive Officer and President at Idera Pharmaceuticals, Inc. since December 1, 2014. Mr. Milano served as the Chief Executive Officer and President of ViroPharma Inc. from March 31, 2008 to January 24, 2014. He served as the Chief Operating Officer of ViroPharma Inc., from January 2006 to March 2008, Vice President from November 1997 to March 2008, Chief Financial Officer from November 1997 to October 2008, Treasurer from July 1996 to 2006 and Principal Accounting Officer until April 2008. Mr. Milano served as an Executive Director of Finance and Administration at ViroPharma Inc., from April 1996 to February 1997 and Vice President of Finance and Administration from February 1997 to November 1997. From 1985 to 1996, he served with KPMG LLP, independent certified public accountants, where he served as Senior Manager since 1991. He joined ViroPharma in April 1996 has led over $400 million of financings, including its initial public offering, follow-on offerings, private placements and convertible debt financings. He served as the Chairman at ViroPharma from December 2008 to January 24, 2014. He has been a Director at Spark Therapeutics, Inc. since June 2014. Mr. Milano has been a Director of BravoSolution US since August 5, 2003 and Pennsylvania Bio since April 20, 2011. He has been Independent Director of Vanda Pharmaceuticals, Inc. since April 21, 2010.He has been Director of VenatoRx and Idera Pharmaceuticals, Inc since 2014. He served as Director of ViroPharma Inc. from February 2008 to January 24, 2014. He has been a Director and a Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He serves as a Director at The Pennsylvania Biotechnology Association. He is a Certified Public Accountant and received his B.S. in Commerce/Accounting from Rider College.

Vuk Koprivica serves as the Senior Director of Business Development of Vanda Pharmaceuticals. Vuk started at Vanda Pharmaceuticals in Dec of 2015. Vuk currently resides in the Washington D.C. Metro Area.